PML Reported in Psoriasis Patients Taking Fumaric Acid Medications in Europe

Two cases of progressive multifocal leukoencephalopathy (PML) in individuals taking either fumaric acid or a compound of fumaric acid esters were reported in The New England Journal of Medicine (N Engl J Med 2013;368;17:1657-1660) on April 25, 2013. PML is a potentially fatal brain infection with the JC virus (JCV), in people with weakened immune systems. Both of these reports were from Europe in individuals receiving long-term treatment for psoriasis (a chronic skin problem that causes skin cells to grow too quickly, resulting in thick, white, silvery, or red patches of skin [WebMD]).

Read News Article

Tecfidera Approved for the Long-Term Treatment of MS

The United States Food and Drug Administration (FDA) announced on March 27, 2013 that it has approved Tecfidera™ (dimethyl fumarate or DMF, formerly known as BG-12) as a first-line therapy for the long-term treatment of relapsing forms of multiple sclerosis (MS). Tecfidera’s parent company, Biogen Idec, submitted a New Drug Application (NDA) to the FDA for the approval of this drug in February 2012. (Read the FDA’s press release on the approval of Tecfidera.)

Read News Article

March is MS Awareness Month

The Multiple Sclerosis Association of America (MSAA) recognizes March as MS Awareness Month. Throughout March, MSAA encourages individuals to expand their knowledge, understanding, and support of individuals whose lives are affected by multiple sclerosis (MS).

Read News Article

The Multiple Sclerosis Association of America Launches New Website

The Multiple Sclerosis Association of America (MSAA) is pleased to introduce its new website, mymsaa.org.

Read News Article

Multiple Sclerosis Association of America Teams Up With SwimOutlet.com To Promote Swim For MS

The Multiple Sclerosis Association of America (MSAA) is pleased to announce its new partnership with SwimOutlet.com to help promote the charity’s national fundraiser, Swim for MS. Serving as the distribution sponsor for Swim for MS, SwimOutlet.com will feature promotional information and ongoing updates on swim events through newsletter articles, targeted email campaigns, and posts on social media including Facebook and Twitter.

Read News Article

Flu and Flu Vaccine Information

Recent news reports and statistical information indicate that this year the incidence rate for seasonal influenza (flu) is already high and is widely impacting communities across the nation. The good news is that the flu immunization prepared for the 2012-2013 flu season appears to be very well matched to those flu strains occurring across the country; therefore, preventative measures such as obtaining a flu vaccine may be helpful in preventing the contraction of the flu.

Read News Article

MSAA’s Mobile Phone App Launches in the Android Marketplace

My MS Manager™, the first-of-its-kind mobile phone application developed to help individuals better manage their MS, is now available on the Android platform. Since its launch in the Apple App Store in June of 2011, My MS Manager has been downloaded more than 9,000 times, with users entering data about their MS on various Apple mobile products.

Read News Article

Emergency and Assistive Services in Response to Hurricane Sandy

The impact of Hurricane Sandy to the residents of the mid-Atlantic, Northeastern, and Midwestern United States has been devastating. MSAA’s staff is deeply saddened by the tragic loss of life as well as the destruction of personal possessions, homes, and businesses, caused by this storm.

Read News Article

Vaccination Safety

Recent studies continue to aff …

Read News Article

Aubagio® (Oral Teriflunomide) Receives FDA Approval

Updated: September 17, 2012 On September 12, 2012, Sanofi and its subsidiary Genzyme announced that the United States Food and Drug Administration (FDA) had approved their new drug, Aubagio® (oral teriflunomide), for relapsing forms of multiple sclerosis (MS). The FDA had accepted their New Drug Application (NDA) in October, 2011.

Read News Article